Investigational Drug Information for Sapacitabine
✉ Email this page to a colleague
What is the development status for investigational drug Sapacitabine?
Sapacitabine is an investigational drug.
There have been 9 clinical trials for Sapacitabine.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2011.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center, and National Cancer Institute (NCI).
Summary for Sapacitabine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 684 |
| WIPO Patent Applications | 494 |
| Japanese Patent Applications | 203 |
| Clinical Trial Progress | Phase 3 (2011-10-01) |
| Vendors | 43 |
Recent Clinical Trials for Sapacitabine
| Title | Sponsor | Phase |
|---|---|---|
| Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | AstraZeneca | Phase 1/Phase 2 |
| Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | Cyclacel Pharmaceuticals, Inc. | Phase 1/Phase 2 |
| Olaparib + Sapacitabine in BRCA Mutant Breast Cancer | Dana-Farber Cancer Institute | Phase 1/Phase 2 |
Clinical Trial Summary for Sapacitabine
Top disease conditions for Sapacitabine
Top clinical trial sponsors for Sapacitabine
US Patents for Sapacitabine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
